StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report report published on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of NASDAQ TTNP opened at $3.67 on Friday. The company has a 50 day simple moving average of $3.49 and a two-hundred day simple moving average of $4.41. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- Pros And Cons Of Monthly Dividend Stocks
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- NYSE Stocks Give Investors a Variety of Quality Options
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
